Zacks: Analysts Anticipate DiaMedica Therapeutics Inc (NASDAQ:DMAC) to Announce -$0.28 EPS

Equities research analysts forecast that DiaMedica Therapeutics Inc (NASDAQ:DMAC) will announce earnings of ($0.28) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for DiaMedica Therapeutics’ earnings. DiaMedica Therapeutics posted earnings per share of ($0.40) during the same quarter last year, which would indicate a positive year-over-year growth rate of 30%. The company is scheduled to issue its next earnings report on Wednesday, September 4th.

On average, analysts expect that DiaMedica Therapeutics will report full-year earnings of ($0.85) per share for the current financial year. For the next financial year, analysts forecast that the company will post earnings of ($1.09) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover DiaMedica Therapeutics.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.05).

Several brokerages have weighed in on DMAC. ValuEngine raised shares of DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research lowered shares of DiaMedica Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Dougherty & Co began coverage on shares of DiaMedica Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $8.00 target price for the company. Finally, Craig Hallum increased their target price on shares of DiaMedica Therapeutics from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. DiaMedica Therapeutics has an average rating of “Buy” and a consensus target price of $8.38.

In related news, Director Richard D. Pilnik bought 19,000 shares of the stock in a transaction on Friday, May 31st. The stock was bought at an average price of $2.80 per share, with a total value of $53,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 12.80% of the company’s stock.

An institutional investor recently bought a new position in DiaMedica Therapeutics stock. Eidelman Virant Capital bought a new position in shares of DiaMedica Therapeutics Inc (NASDAQ:DMAC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 35,000 shares of the company’s stock, valued at approximately $173,000. Eidelman Virant Capital owned 0.29% of DiaMedica Therapeutics at the end of the most recent reporting period. 8.78% of the stock is currently owned by institutional investors.

DMAC stock traded up $0.13 during mid-day trading on Friday, hitting $3.51. 31,729 shares of the company were exchanged, compared to its average volume of 56,277. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.49 and a quick ratio of 10.49. The firm’s fifty day simple moving average is $4.15. DiaMedica Therapeutics has a 12-month low of $2.46 and a 12-month high of $5.93.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Featured Article: What is the Quick Ratio?

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with's FREE daily email newsletter.